ClinicalTrials.gg
CompletedNCT00652925Updated May 30, 2008

A Study to Evaluate the Efficacy and Safety of Celecoxib Suspension Compared to Naproxen Suspension in Patients With JRA

A Phase 3 interventional study of Celecoxib and Celecoxib in Arthritis, Juvenile Rheumatoid, sponsored by Pfizer. Completed at 58 sites in 15 countries. Open to participants aged 2 Years to 18 Years. Per ClinicalTrials.gov, last updated 2008-05-30.

Sponsored by Pfizer · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
225
Allocation
Randomized
Ages
2 Years to 18 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 10 studies in Arthritis, Juvenile by Pfizer — 1 open to participants now, 1 under way, none of them phase 3. Arthritis, Juvenile · Pfizer.

Started
2002
the only one that year
Phase 3
4 of 10
none open now
Registered
3rd of 10
by date

Among the 10 studies in Arthritis, Juvenile by Pfizer, this one is the only one that started in 2002, is one of 4 in phase 3, and was the 3rd registered.

Arthritis, Juvenile

366 studies on the registry are indexed under Arthritis, Juvenile; 102 are open to participants now.

Browse Arthritis, Juvenile studies →

Open to participants now

1 of the 10 studies in Arthritis, Juvenile by Pfizer is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

Who these studies take

Of the 69 Arthritis, Juvenile studies recruiting now, 13 (19%) set no upper age limit and 50 (72%) stop at 75 or younger; 65 take children under 18; 11 take healthy volunteers.

This study: 2 Years to 18 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies in Arthritis, Juvenile by Pfizer, or all of them as a file.
02

Study summary

To study Celebrex versus naproxen to see if it decreases symptoms of juvenile arthritis such as pain and swelling.

03

Conditions studied

  • Arthritis, Juvenile Rheumatoid

Keywords

  • arthritis
  • juvenile
04

Who can participate

Ages eligible
2 Years to 18 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

2-18 years old with active JRA

Exclusion criteria

Exclusion Criteria:

other experimental meds, recent changes in arthritis meds

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
225 participants (actual)

Study arms

  • Experimental
    High Dose

    Drug: Celecoxib

  • Experimental
    Low Dose

    Drug: Celecoxib

  • Active comparator
    Naproxen

    Control comparator, 15 mg/kg/dy target dose

    Drug: Naproxen

Interventions

  • Higher dose, 6 mg/kg/dose BID

  • Active drug at lower dose

  • Control comparator, 15 mg/kg/dy target dose

06

What researchers measure

Primary outcomes

  1. ACR Pediatric 30

    Time frame: 12 weeks

Secondary outcomes

  1. Peds QOL

    Time frame: 12 weeks

  2. composites of acr 30

    Time frame: 12 weeks

07

Study locations

58 sites
  • Pfizer Investigational Site
    San Diego, California 92123, United States
  • Pfizer Investigational Site
    Hartford, Connecticut 06106, United States
  • Pfizer Investigational Site
    Delray Beach, Florida 33484, United States
  • Pfizer Investigational Site
    Miami, Florida 33155, United States
  • Pfizer Investigational Site
    St. Petersburg, Florida 33701, United States
  • Pfizer Investigational Site
    Chicago, Illinois 60614, United States
  • Pfizer Investigational Site
    Chicago, Illinois 60637, United States
  • Pfizer Investigational Site
    Chicago, Illinois 60649, United States
  • Pfizer Investigational Site
    Glenview, Illinois 60025, United States
  • Pfizer Investigational Site
    Hinsdale, Illinois 60521, United States
  • Pfizer Investigational Site
    Merrillville, Indiana 46410, United States
  • Pfizer Investigational Site
    New Orleans, Louisiana 70118, United States
  • Pfizer Investigational Site
    Boston, Massachusetts 02115, United States
  • Pfizer Investigational Site
    Worcester, Massachusetts 01610, United States
  • Pfizer Investigational Site
    Omaha, Nebraska 68178, United States
  • Pfizer Investigational Site
    Livingston, New Jersey 07039, United States
  • Pfizer Investigational Site
    New Hyde Park, New York 11040, United States
  • Pfizer Investigational Site
    New York, New York 10032, United States
  • Pfizer Investigational Site
    Tulsa, Oklahoma 74133, United States
  • Pfizer Investigational Site
    Tulsa, Oklahoma 74135, United States
  • Pfizer Investigational Site
    Portland, Oregon 97210, United States
  • Pfizer Investigational Site
    Portland, Oregon 97227-1623, United States
  • Pfizer Investigational Site
    Portland, Oregon 97232, United States
  • Pfizer Investigational Site
    Altoona, Pennsylvania 16601, United States
  • Pfizer Investigational Site
    Altoona, Pennsylvania 16602, United States
  • Pfizer Investigational Site
    Duncansville, Pennsylvania 16635, United States
  • Pfizer Investigational Site
    Hershey, Pennsylvania 17033, United States
  • Pfizer Investigational Site
    Johnstown, Pennsylvania 15904, United States
  • Pfizer Investigational Site
    Lancaster, Pennsylvania 17604, United States
  • Pfizer Investigational Site
    Milwaukee, Wisconsin 53201, United States
  • Pfizer Investigational Site
    Milwaukee, Wisconsin 53226-0509, United States
  • Pfizer Investigational Site
    Leuven, 3000, Belgium
  • Pfizer Investigational Site
    Rio De Janeiro, RJ 20551-030, Brazil
  • Pfizer Investigational Site
    São Paulo, SP 04025-002, Brazil
  • Pfizer Investigational Site
    São Paulo, SP 05403-901, Brazil
  • Pfizer Investigational Site
    Rio de Janeiro, 21944-970, Brazil
  • Pfizer Investigational Site
    Saskatoon, Saskatchewan, Canada
  • Pfizer Investigational Site
    Århus N, 8200, Denmark
  • Pfizer Investigational Site
    Vandoeuvre-les-nancy, 54511, France
  • Pfizer Investigational Site
    Berlin, 13125, Germany
  • Pfizer Investigational Site
    Bremen, 28205, Germany
  • Pfizer Investigational Site
    Halle, 06120, Germany
  • Pfizer Investigational Site
    Hamburg, 22081, Germany
  • Pfizer Investigational Site
    Hannover, 30625, Germany
  • Pfizer Investigational Site
    Monterrey, Nuevo Leon 64460, Mexico
  • Pfizer Investigational Site
    Guadalajara, 44650, Mexico
  • Pfizer Investigational Site
    Lima, L05, Peru
  • Pfizer Investigational Site
    Lima, L13, Peru
  • Pfizer Investigational Site
    Lima, L31, Peru
  • Pfizer Investigational Site
    Vila Nova de Famalicao, 4764-901, Portugal
  • Pfizer Investigational Site
    Moscow, 115522, Russian Federation
  • Pfizer Investigational Site
    Moscow, 119296, Russian Federation
  • Pfizer Investigational Site
    Piestany, 921 01, Slovakia
  • Pfizer Investigational Site
    Ljubljana, 1525, Slovenia
  • Pfizer Investigational Site
    Madrid, 28009, Spain
  • Pfizer Investigational Site
    Madrid, 28034, Spain
  • Pfizer Investigational Site
    Valencia, 46009, Spain
  • Pfizer Investigational Site
    Stockholm, SE-17176, Sweden
08

References and documents

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2002, a primary completion of Apr 2004 and a completion of Apr 2005. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 1, 2008
First posted
Apr 4, 2008
Start
Oct 2002
Primary completionActual
Apr 2004
CompletionActual
Apr 2005
Last update
May 30, 2008
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 30, 2008, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00652925
Lead sponsor
Pfizer
First posted
Apr 4, 2008
Start date
Oct 2002
Primary completion
Apr 2004
Completion
Apr 2005
Last update
May 30, 2008

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2008. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Celecoxib

Start the discussion